Genmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Expectations By $2.15 EPS

Genmab A/S (OTCMKTS:GNMSF) announced its earnings results on Thursday. The company reported $5.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.49 by $2.15, Zacks reports. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%.

Genmab A/S Stock Down 1.5%

GNMSF traded down $8.00 on Thursday, reaching $538.00. The company’s stock had a trading volume of 100 shares, compared to its average volume of 5,854. Genmab A/S has a 1 year low of $232.34 and a 1 year high of $581.00. The business’s 50 day moving average is $387.72 and its 200 day moving average is $309.34. The company has a debt-to-equity ratio of 0.81, a current ratio of 2.46 and a quick ratio of 2.44. The stock has a market cap of $33.12 billion, a price-to-earnings ratio of 42.20 and a beta of 0.64.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary technologies to create differentiated antibodies and antibody-drug conjugates designed to engage the immune system or target specific disease-related proteins.

Genmab’s technologies include the DuoBody platform for generating bispecific antibodies, as well as the HexaBody platform for developing antibodies with enhanced activity.